Barclays Reiterates “Equal weight” Rating for Amlin (AML)
Amlin (LON:AML)‘s stock had its “equal weight” rating restated by research analysts at Barclays in a report released on Tuesday, AnalystRatings.Net reports.
A number of other analysts have also recently weighed in on AML. Analysts at Canaccord Genuity raised their price target on shares of Amlin from GBX 420 ($6.90) to GBX 430 ($7.07) in a research note to investors on Friday. They now have a “hold” rating on the stock. Separately, analysts at Westhouse Securities reiterated an “add” rating on shares of Amlin in a research note to investors on Thursday, January 30th. Finally, analysts at HSBC cut their price target on shares of Amlin from GBX 430 ($7.07) to GBX 415 ($6.82) in a research note to investors on Tuesday, January 21st. They now have an “underweight” rating on the stock. Six equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have issued a buy rating to the company. Amlin currently has an average rating of “Hold” and an average target price of GBX 431.13 ($7.09).
Shares of Amlin (LON:AML) opened at 415.50 on Tuesday. Amlin has a 52-week low of GBX 372.10 and a 52-week high of GBX 463.50. The stock has a 50-day moving average of GBX 436.3 and a 200-day moving average of GBX 418.5. The company’s market cap is £2.074 billion.
Amlin plc is engaged in non-life insurance and reinsurance underwriting in the Lloyd’s market, Bermuda and Continental Europe.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.